Skip to content
IP + Technology Law
Home  »  News & Insights  »  Publications

Lessons From The 1st Biopharma Inter Partes Reviews | Law360

April 16, 2015  | Eli A. Loots, Ph.D.

Recently, the Patent Trial and Appeal Board issued its first set of final written decisions in three inter partes reviews relating to molecules in the large molecule biopharma space (IPR2013-00534, IPR2013- 00535 and IPR2013-00537). Biosimilar companies will no doubt be looking to these decisions as a roadmap for clearing patent landscapes for their own biosimilar products in the coming years. Read more below or download the PDF.

Lessons From The 1st Biopharma Inter Partes Reviews from Knobbe Martens Olson & Bear

Related Links

Practice Areas

Industries

News & Insights

News
Mar 2026
Sheila Swaroop Comments on USPTO Memo on U.S. Manufacturing Factors in AIA Reviews
In the Law360 article “Manufacturing Factor Adds More New Twists to AIA Cases,” Knobbe Martens partner Sheila Swaroop weighed in on the U.S. Patent & Trademark Office’s latest memo regarding...
Publications
Mar 2026
USPTO Director to Consider U.S. Manufacturing and Small Business Status When Instituting or Denying IPR and PGR Petitions
Key Takeaways Effective immediately, the USPTO will consider whether a patent challenger’s accused products or a patent owner’s products are manufactured in the United States as additional factors in the...
Publications
Apr 2026
Jeremiah Helm and Sean Murray Discuss Federal Circuit Decision on Patent Claim Language in Law360 Article
Knobbe Martens partners Jeremiah Helm and Sean Murray explored the Federal Circuit’s opinion on patent claim construction in Netflix Inc. v. DivX LLC in their latest Law360 column on the...